Abstract
The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.
Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum
Current Pharmaceutical Biotechnology
Title:Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Volume: 14 Issue: 1
Author(s): Alexander Hawlitschka, Veronica Antipova, Oliver Schmitt, Martin Witt, Reiner Benecke, Eilhard Mix and Andreas Wree
Affiliation:
Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum
Abstract: The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.
Export Options
About this article
Cite this article as:
Hawlitschka Alexander, Antipova Veronica, Schmitt Oliver, Witt Martin, Benecke Reiner, Mix Eilhard and Wree Andreas, Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010015
DOI https://dx.doi.org/10.2174/1389201011314010015 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Efficient Synthesis of 5-Arylmethyl-5-phenylimidazolidine-2,4-dione (or 5-Arylmethyl-5-phenyl-2-thioxoimidazolidin-4-one) from Chalcone Oxides Under Ultrasound Irradiation
Letters in Organic Chemistry Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Current Psychopharmacology Screening of Some Novel 4, 5 Disubstituted 1, 2, 4-Triazole-3-thiones for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Current Topics in Medicinal Chemistry Prediction of an Interaction between Bakuchiol and Acetylcholinesterase using Adaboost
Current Bioinformatics Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Clinical Profile of Mortality among Chronic Schizophrenic Patients: A Local Pilot Survey in Iran
Current Psychiatry Research and Reviews Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Recent Multiple Transition Metal Catalysed Single-Pot Reactions
Current Organic Synthesis The Challenge of microRNA as a Biomarker of Epilepsy
Current Neuropharmacology Semicarbazone Analogs as Anticonvulsant Agents: A Review
Central Nervous System Agents in Medicinal Chemistry New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Decreased Valproate Level Caused by VPA-glucuronidase Inhibition by Carbapenem Antibiotics
Drug Metabolism Letters Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Editorial [Hot topic: Chemical Agents Positively and Negatively Affecting the Central Nervous System (Guest Editors: Abel Santamaria & Mauricio Diaz-Munoz)]
Central Nervous System Agents in Medicinal Chemistry 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry